Patents by Inventor Christopher Claiborne

Christopher Claiborne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoquinolinone potassium channel inhibitors
    Patent number: 8338449
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: December 25, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: B. Wesley Trotter, Christopher Claiborne, Gerald S. Ponticello, Charles J. McIntyre, Nigel Liverton, David A. Claremon
  • Keyboard with split layout
    Publication number: 20110249999
    Abstract: An apparatus and layout for manual text entry on a small form factor information processing device provides a keyboard for data entry located on the back side of the device, opposite the side of the device facing the user. The keyboard assembly is further laid out as a split of the layout of the conventional standard form factor keyboard adapted to touch-typing, enabling users to employ touch-typing expertise acquired on standard keyboards on the small form-factor device.
    Type: Application
    Filed: April 7, 2010
    Publication date: October 13, 2011
    Inventors: Andrew Boer, Christopher Claiborne
  • Isoquinolinone Potassium Channel Inhibitors
    Publication number: 20100256698
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: April 2, 2010
    Publication date: October 7, 2010
    Applicant: MERCK & CO., INC.
    Inventors: B. Wesley Trotter, Christopher Claiborne, Gerald S. Ponticello, Charles J. McIntyre, Nigel Liverton, David A. Claremon
  • Isoquinolinone potassium channel inhibitors
    Patent number: 7723352
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: May 25, 2010
    Assignee: Merck Sharp & Dohme
    Inventors: B. Wesley Trotter, Christopher Claiborne, Gerald S. Ponticello, Charles J. McIntyre, Nigel Liverton, David A. Claremon
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Publication number: 20080051404
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: August 6, 2007
    Publication date: February 28, 2008
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Claiborne, Stephen Critchley, Courtney Cullis, Steven Langston, Hiro Mizutani, Edward Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel Weatherhead
  • Pyridobenzazepine compounds and methods for inhibiting mitotic progression
    Publication number: 20080045501
    Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Application
    Filed: August 6, 2007
    Publication date: February 21, 2008
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Claiborne, Todd Sells, Stephen Stroud
  • N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
    Publication number: 20070149568
    Abstract: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMD NR2B antagonists useful for treating conditions such as, for example, Parkinson's disease, Alzheimer's disease, migraine, epilepsy and pain.
    Type: Application
    Filed: March 10, 2004
    Publication date: June 28, 2007
    Inventors: Nigel Liverton, Christopher Claiborne, David Claremon, John McCauley
  • Isoquinolinone potassium channel inhibitors
    Publication number: 20070027177
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 17, 2004
    Publication date: February 1, 2007
    Inventors: B. Trotter, Christopher Claiborne, Gerald Ponticello, Charles McIntyre, Nigel Liverton, David Claremon
  • Lactam compounds useful as protein kinase inhibitors
    Publication number: 20060100194
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: October 3, 2005
    Publication date: May 11, 2006
    Inventors: Christopher Blackburn, Christopher Claiborne, Courtney Cullis, Natalie Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel Weatherhead
  • Compounds and methods for inhibiting mitotic progression
    Publication number: 20050256102
    Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Application
    Filed: May 12, 2005
    Publication date: November 17, 2005
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Claiborne, Lloyd Payne, Richard Boyce, Todd Sells, Stephen Stroud, Stuart Travers, Tricia Vos, Gabriel Weatherhead